Limits...
Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer.

He SM, Xing F, Sui H, Wu Y, Wang Y, Wang D, Chen G, Kong Z, Zhou SF - Med. Sci. Monit. (2011)

Bottom Line: Serum CA-125 has been used as a biomarker of gynecological tumors.The increase of CA-125 content in serum, cervical and vaginal secretions was lesser significant in grade 3 cancer than that in grade 1 and 2 cancer.Generally, serum CA-125 levels correlated with those in cervical and vaginal secretions and CA-125 content in cervical secretion correlated with that in vaginal secretion.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Xiaolan Hospital Affiliated to Southern Medical University, Zhongshan, China. heshuming@zsxlyy.com

ABSTRACT

Background: Serum CA-125 has been used as a biomarker of gynecological tumors. In this study, we investigated the CA-125 levels in cervical and vaginal secretions from Chinese patients with endometrial polyps, hyperplasia and carcinoma in comparison with those in endometrium and serum.

Material/methods: An electro-chemiluminescent immunoassay was utilized to determine the levels of CA-125 in 51 healthy Chinese women and 97 patients with polyps, hyperplasia or endometrial cancer. An immunohistochemistry method was used to detect endometrial CA-125 expression in 242 subjects.

Results: Our study demonstrated that serum CA-125 levels were much lower than those in cervical and vaginal secretions in healthy and diseased women. The levels of CA-125 in serum, and cervical and vaginal secretions were significantly increased in complex hyperplasia and endometrial cancer. The increase of CA-125 content in serum, cervical and vaginal secretions was lesser significant in grade 3 cancer than that in grade 1 and 2 cancer. Generally, serum CA-125 levels correlated with those in cervical and vaginal secretions and CA-125 content in cervical secretion correlated with that in vaginal secretion. There was only a weak CA-125 expression in normal endometrium and simple endometrial hyperplasia. There was a significant difference in CA-125 expression among patients with pathological grade 1, 2 and 3 of endometrial carcinoma.

Conclusions: Endo.metrial CA-125 expression together with its levels in the serum and cervical and vaginal secretions can be used as a potential biomarker in the diagnosis of precancerous diseases and endometrial carcinoma.

Show MeSH

Related in: MedlinePlus

Endometrial staining of CA-125 in different groups of subjects (magnification × 400). (A) proliferative phase endometrium; (B) secretory phase endometrium; (C) non-functional endometrial polyps; (D) simple hyperplasia.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539493&req=5

f1-medscimonit-17-11-cr618: Endometrial staining of CA-125 in different groups of subjects (magnification × 400). (A) proliferative phase endometrium; (B) secretory phase endometrium; (C) non-functional endometrial polyps; (D) simple hyperplasia.

Mentions: In 123 cases of endometrial cancer, 63, 42 and 18 were pathological grade 1, 2, and 3, respectively (Table 2). Overall, In 63 cases of grade 1 endometrial cancer, 33 and 30 showed score 2 and 3 staining of CA-125, respectively (Figure 1). This figure was 14 and 28 in 42 cases of grade 2 endometrial cancer. In 18 cases of grade 3 endometrial carcinoma, 16 and 2 displayed score 2 and 3 staining of CA-125, respectively. Overall, 63 (51.22%) and 60 (48.78%) subjects of 123 cases showed score 2 and 3 staining of endometrial CA-125, respectively. There was a significant difference in endometrial CA-125 expression among patients with pathological grade 1, 2 and 3 of endometrial carcinoma (χ2=15.632, P=0.0004). The endometrial expression of CA-125 in each grade of cancer was significantly different from that of normal endometrium. There was a significant difference in CA-125 expression between grade 1 and 3 endometrial carcinoma (P=0.0058 by Fisher’s exact test) whereas there was no significant difference in CA-125 expression between grade 1 and 2 endometrial carcinoma (P=0.0717 by Fisher’s exact test). In addition, there was a significant difference in CA-125 expression between grade 2 and 3 endometrial carcinoma (P=0.0001 by Fisher’s exact test).


Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer.

He SM, Xing F, Sui H, Wu Y, Wang Y, Wang D, Chen G, Kong Z, Zhou SF - Med. Sci. Monit. (2011)

Endometrial staining of CA-125 in different groups of subjects (magnification × 400). (A) proliferative phase endometrium; (B) secretory phase endometrium; (C) non-functional endometrial polyps; (D) simple hyperplasia.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539493&req=5

f1-medscimonit-17-11-cr618: Endometrial staining of CA-125 in different groups of subjects (magnification × 400). (A) proliferative phase endometrium; (B) secretory phase endometrium; (C) non-functional endometrial polyps; (D) simple hyperplasia.
Mentions: In 123 cases of endometrial cancer, 63, 42 and 18 were pathological grade 1, 2, and 3, respectively (Table 2). Overall, In 63 cases of grade 1 endometrial cancer, 33 and 30 showed score 2 and 3 staining of CA-125, respectively (Figure 1). This figure was 14 and 28 in 42 cases of grade 2 endometrial cancer. In 18 cases of grade 3 endometrial carcinoma, 16 and 2 displayed score 2 and 3 staining of CA-125, respectively. Overall, 63 (51.22%) and 60 (48.78%) subjects of 123 cases showed score 2 and 3 staining of endometrial CA-125, respectively. There was a significant difference in endometrial CA-125 expression among patients with pathological grade 1, 2 and 3 of endometrial carcinoma (χ2=15.632, P=0.0004). The endometrial expression of CA-125 in each grade of cancer was significantly different from that of normal endometrium. There was a significant difference in CA-125 expression between grade 1 and 3 endometrial carcinoma (P=0.0058 by Fisher’s exact test) whereas there was no significant difference in CA-125 expression between grade 1 and 2 endometrial carcinoma (P=0.0717 by Fisher’s exact test). In addition, there was a significant difference in CA-125 expression between grade 2 and 3 endometrial carcinoma (P=0.0001 by Fisher’s exact test).

Bottom Line: Serum CA-125 has been used as a biomarker of gynecological tumors.The increase of CA-125 content in serum, cervical and vaginal secretions was lesser significant in grade 3 cancer than that in grade 1 and 2 cancer.Generally, serum CA-125 levels correlated with those in cervical and vaginal secretions and CA-125 content in cervical secretion correlated with that in vaginal secretion.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Xiaolan Hospital Affiliated to Southern Medical University, Zhongshan, China. heshuming@zsxlyy.com

ABSTRACT

Background: Serum CA-125 has been used as a biomarker of gynecological tumors. In this study, we investigated the CA-125 levels in cervical and vaginal secretions from Chinese patients with endometrial polyps, hyperplasia and carcinoma in comparison with those in endometrium and serum.

Material/methods: An electro-chemiluminescent immunoassay was utilized to determine the levels of CA-125 in 51 healthy Chinese women and 97 patients with polyps, hyperplasia or endometrial cancer. An immunohistochemistry method was used to detect endometrial CA-125 expression in 242 subjects.

Results: Our study demonstrated that serum CA-125 levels were much lower than those in cervical and vaginal secretions in healthy and diseased women. The levels of CA-125 in serum, and cervical and vaginal secretions were significantly increased in complex hyperplasia and endometrial cancer. The increase of CA-125 content in serum, cervical and vaginal secretions was lesser significant in grade 3 cancer than that in grade 1 and 2 cancer. Generally, serum CA-125 levels correlated with those in cervical and vaginal secretions and CA-125 content in cervical secretion correlated with that in vaginal secretion. There was only a weak CA-125 expression in normal endometrium and simple endometrial hyperplasia. There was a significant difference in CA-125 expression among patients with pathological grade 1, 2 and 3 of endometrial carcinoma.

Conclusions: Endo.metrial CA-125 expression together with its levels in the serum and cervical and vaginal secretions can be used as a potential biomarker in the diagnosis of precancerous diseases and endometrial carcinoma.

Show MeSH
Related in: MedlinePlus